Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 12:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 6,067 matching trials from the live ClinicalTrials.gov search.
Conditions
Kidney Diseases, Coronary Artery Disease
Interventions
Regadenoson, Placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
511 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
41
States / cities
Anniston, Alabama • Little Rock, Arkansas • Bell Gardens, California + 36 more
Terminated Phase 2 Interventional Results available

A Phase II Study of M2951 in SLE

NCT02975336
Conditions
Systemic Lupus Erythematosus
Interventions
Placebo, M2951
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
469 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
42
States / cities
Anniston, Alabama • Mesa, Arizona • Phoenix, Arizona + 37 more
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Conditions
Crohn Disease
Interventions
Etrolizumab, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
62
States / cities
Arcadia, California • La Jolla, California • Long Beach, California + 53 more
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Conditions
Type 2 Diabetes Mellitus
Interventions
INT131 besylate, Pioglitazone HCl, Placebo
Drug
Lead sponsor
InteKrin Therapeutics, Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
59
States / cities
Carmichael, California • Los Angeles, California • San Diego, California + 48 more
Conditions
Neoplasms, Prostate
Interventions
Dutasteride, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years to 75 Years · Male only
Enrollment
8,231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
297
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 236 more
Completed Not applicable Interventional Accepts healthy volunteers

Physical Activity Referrals to the Community

NCT02044744
Conditions
Overweight, Obesity
Interventions
Physical activity referral
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
6 Years to 18 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
4
States / cities
San Francisco, California
Conditions
Retraction of Ileostomy
Interventions
Ileostomy Reversal using Self Forming Magnets (SFM)
Device
Lead sponsor
GI Windows, Inc.
Industry
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
14
States / cities
Orlando, Florida • Boston, Massachusetts • Worcester, Massachusetts + 10 more
Conditions
Attention Deficit Hyperactivity Disorder (ADHD)
Interventions
SHP465 12.5mg capsules (one capsule daily), Placebo, SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
45
States / cities
Encino, California • Los Alamitos, California • Newport Beach, California + 40 more
Conditions
Methamphetamine Use Disorder
Interventions
Pomaglumetad methionil, Placebo, Methamphetamine
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Santa Monica, California
Conditions
Idiopathic Pulmonary Fibrosis
Interventions
NAL ER, Placebo
Drug
Lead sponsor
Trevi Therapeutics
Industry
Eligibility
40 Years and older
Enrollment
306 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
22
States / cities
Newport Beach, California • Palm Springs, California • Redding, California + 19 more
Conditions
CACNA1A, Spinocerebellar Ataxia Type 6, Episodic Ataxia Type 2, Familial Hemiplegic Migraine-1
Interventions
N-Acetyl-L-Leucine, Placebo
Drug · Other
Lead sponsor
IntraBio Inc
Industry
Eligibility
4 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
3
States / cities
Baltimore, Maryland • Boston, Massachusetts • Houston, Texas
Completed Not applicable Interventional Accepts healthy volunteers

Dimensional Brain Behavior Predictors of CBT Outcomes in Pediatric Anxiety

NCT02810171
Conditions
Anxiety Disorders, Social Anxiety Disorder, Social Phobia, Generalized Anxiety Disorder, Separation Anxiety Disorder, Specific Phobia, Phobia, Agoraphobia, Panic Disorder, Panic Attack, Anxiety
Interventions
Cognitive Behavioral Therapy, Relaxation Therapy
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
7 Years to 17 Years
Enrollment
207 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Conditions
Chronic Ankle Instability
Interventions
Real-world vibration feedback gait retraining
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 35 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
End Stage Kidney Disease, Depressive Symptoms
Interventions
Joviality(TM), Inert Virtual Reality
Behavioral · Other
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
21 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Chicago, Illinois
Conditions
Long COVID, Long COVID-19, Hypersomnia
Interventions
Modafinil, Modafinil Placebo, Solriamfetol, Solriamfetol Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
361 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Crohn Disease
Interventions
JNJ-67864238, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Colorado Springs, Colorado • Clearwater, Florida • Macon, Georgia + 10 more
Conditions
Asthma
Interventions
QAW039, Placebo QAW039, Fluticasone 250 mcg, Fluticasone 100 mcg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
30
States / cities
Encinitas, California • Huntington Beach, California • Los Angeles, California + 24 more
Conditions
T2DM (Type 2 Diabetes Mellitus)
Interventions
Cohort A: ORMD-0801, Placebo oral capsule, Cohort B: ORMD-0801
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Flint, Michigan
Conditions
Down Syndrome, Autonomic Dysfunction
Interventions
Cold Stress, Maximal Dynamic Exercise, Isometric Handgrip Exercise with Post-Exercise Muscle Ischemia, Head-up Tilt Table Test
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 50 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.

NCT06481098
Conditions
Obesity
Interventions
HM15275, Placebo of HM15275
Drug
Lead sponsor
Hanmi Pharmaceutical Company Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Primary Biliary Cholangitis
Interventions
Saroglitazar magnesium 1 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
386 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
Marietta, Georgia • Indianapolis, Indiana • Houston, Texas